Rising Cancer Prevalence Drives Demand for Targeted Therapy: Market Forecast to Reach $140.77B by 2028

The targeted therapy market size has grown strongly in recent years. It will grow from $97.72 billion in 2023 to $105.06 billion in 2024 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to advancements in molecular biology, increasing cancer incidence, personalized medicine trend, FDA approvals and regulatory support.

The targeted therapy market size is expected to see strong growth in the next few years. It will grow to $140.77 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to expanding oncology research, rising demand for precision medicine, emergence of immunotherapies, growing investment in biopharmaceuticals, patient awareness and advocacy. Major trends in the forecast period include integration of artificial intelligence (AI) in drug discovery, patient advocacy and involvement in treatment decisions, expansion of companion diagnostics, regulatory support for expedited approvals, increasing investment in biotechnology and pharma.

Market Overview -
Targeted therapy refers to a kind of cancer treatment that employs medications or other chemicals to attack particular molecules required for the survival and spread of cancer cells. It uses drugs to target specific genes and proteins that help cancer cells survive and grow.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=9129&type=smp

Rising Cancer Prevalence Fuels Surge In Demand For Targeted Therapy
The increasing prevalence of cancer is expected to propel the growth of the targeted therapy market going forward. Cancer is a term for conditions where aberrant cells can infect surrounding tissues and divide uncontrollably. Targeted therapy can disable the signals that encourage the growth of cancer cells or signal the cancer cells to self-destruct. It employs medication to specifically target genes and proteins that support the growth and survival of cancer cells, thus increasing its demand. For instance, in September 2021, according to the National Cancer Institute, a US-based government organization that is a part of the National Institutes of Health, reported that 1,806,590 new cancer cases were registered, which indicated a 43% increase from previous year. Therefore, the increasing prevalence of cancer is driving the growth of the targeted therapy market.

Competitive Landscape -
Major companies operating in the targeted therapy market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Genmab A/S, Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Agilent Technologies Inc., Illumina Inc., Incyte Corporation, Sysmex Corporation, Exact Sciences Corporation, Seagen Inc., Exelixis Inc., Seattle Genetics Inc., Genentech Inc., Daiichi Sankyo Company Limited, ChemGenex Pharmaceuticals Ltd

Advanced Targeted Therapy Market With FDA Approval
Major companies operating in the targeted therapy market are focused on developing new technological solutions to strengthen their position in the market. For instance, in March 2022, Novartis AG, a Switzerland-based multinational pharmaceutical corporation, launched Pluvicto, which was approved by the US Food and Drug Administration (FDA). Pluvicto is the first FDA-approved targeted radioligand therapy (RLT) for eligible patients with mCRPC. It combines a therapeutic radioisotope with a targeted chemical (a radioactive particle). It is a type of targeted cancer therapy in which a therapeutic radioisotope is combined with a targeting chemical. Pluvicto binds to target cells in the circulation, including prostate cancer cells that express the transmembrane protein PSMA. When bonded, the radioisotope's energy emissions injure the target cells as well as other cells in the region, inhibiting replication and/or leading to cell death.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report

Key Segments -
The targeted therapy market covered in this report is segmented -
1) By Type: Small Molecule Medicines, Monoclonal Antibodies
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Lymphoma, Renal Cancer, Other Applications

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.